Clinical pharmacology of dopamine agonists

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

With the availability of newer dopamine agonists selective for dopamine (D2) receptor subtypes, medical management of Parkinson's disease has progressed substantially. These agents can decrease the frequency of ergot- related side effects and dyskinesias. Also, when given as adjunctive therapy with levodopa, they can allow the levodopa maintenance dosage to be reduced without loss of symptom control. Based on early clinical experience, dopamine agonists can also be prescribed as initial monotherapy and can delay therapy with levodopa. Their therapeutic roles will be defined further by long-term studies.

Original languageEnglish (US)
Pages (from-to)17S-25S
JournalPharmacotherapy
Volume20
Issue number1 II
Publication statusPublished - Jan 24 2000

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this